Mr. Lahav Gil reports

CHROMEDX APPOINTS TOM GLAWDEL AS CHIEF SCIENTIFIC OFFICER AND HEMOPALM SCIENCE LEAD

ChroMedX Corp. has appointed Dr. Tom Glawdel, PhD, as chief scientific officer and HemoPalm (HP) science lead, effective immediately.

Dr. Glawdel is a decorated PhD in mechanical and mechatronics engineering from the University of Waterloo. He has experience in the development of microfluidic, molecular diagnostics, RUO products and medical devices (both internal and through strategic research partnerships). Dr. Glawdel has authored more than 30 academic publications and patent applications.

"I am very happy to be welcoming Tom to the team as chief scientific officer and science lead for the HemoPalm platform" said Lahav Gil, chief executive officer of ChroMedX. "Tom has a rare combination of scientific and engineering training, combined with core knowledge in microfluidics and biosensors development. On top of that, he has a great understanding of commercialization strategies and business considerations. This makes him an excellent leader and team member in a med-tech incubator/accelerator like ours. Beyond that, his ability to manage the thinking process around complex issues and bring clarity to the discussion is remarkable."

As chief scientific officer and HemoPalm lead, Dr. Glawdel will be responsible for managing the development of the company's sensor technologies and the single-use cartridge for the HP, as well as provide key scientific input into additional projects and products as the company expands. He is currently building out the lab, accelerating HP prototype development and managing the IP portfolio.

Dr. Glawdel began his career in the industry at Stemcell Technologies in bioengineering research and development, developing novel technologies for cell separation and purification, and cell culture for the stem cell research market.

Following this, Dr. Glawdel held escalating positions at Xagenic Inc., a privately held molecular diagnostics company developing a fully automated molecular diagnostic platform. Dr. Glawdel assisted in managing research initiatives and product development for a team of 20 researchers, developed data analytics methods and tools for processing experimental data across research, quality and manufacturing groups, and guided research and development of a novel molecular diagnostic platform.

The company also announces that it has granted an aggregate of 4,017,500 options to purchase common shares of the company (exercisable at today's closing price and expiring on June 21, 2023) to certain directors, officers, employees and consultants of the company.

Recent news

Earlier this week, the company announced the expansion of its operations into an integrated med-tech incubator/accelerator platform. The formal name change will take place following the company's annual general meeting on June 29, 2018.

As Relay Medical, the company will develop and productize multiple products and projects concurrently, as well as vet strategic acquisitions that are complimentary to current infrastructure assets. Acquisitions and continuing vetting of projects will be governed by robust criteria and a disciplined process supported by an independent investment committee. By sourcing technologies and integrating the financing and development of products in one organization, led and managed by one expert team, Relay Medical is building the capacity to develop and transact technologies with high efficiency.

About ChroMedX Corp.

ChroMedX is a medical technology company focused on the development of novel, hand-held medical devices for diagnostic testing.

We seek Safe Harbor.